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Abstract
Background Allograft function following renal transplanta-
tion is commonly monitored using serum creatinine. Multi-
ple cross-sectional studies have shown that serum cystatin C
is superior to creatinine for detection of mild to moderate
chronic kidney dysfunction. Recent data in adults indicate
that cystatin C might also be a more sensitive marker of
acute renal dysfunction. This study aims to compare cystatin
C and creatinine for detection of acute allograft dysfunction
in children using pediatric RIFLE (risk of renal dysfunction,
injury to the kidney, failure or loss of kidney function, end
stage renal disease) criteria for acute kidney injury.
Methods Retrospective chart review of post-transplant peri-
od in 24 patients in whom creatinine and cystatin C were
measured every day. Allograft dysfunction was defined as a
sustained rise in marker concentration above the mean of the
three preceding measurements.
Results In total, there were 13 episodes of allograft dysfunc-
tion. Maximum RIFLE stages with creatinine were 'R' in 7,
'I' in 4, and 'F' in 2, with cystatin C ‘R’ in 6, ‘I’ in 4 and ‘F’
in 3, respectively. In 9/13 cases, both markers rose simulta-
neously, in three, the rise in creatinine preceded cystatin C
by 1–5 days (median 4). In one case, the rise in cystatin C
preceded creatinine by 1 day. The time lag was not statisti-
cally different. The maximum relative rise of creatinine was
significantly higher than cystatin C. By multiple linear re-
gression analysis, the maximum rise of cystatin C was
related to the maximum rise of creatinine, but independent
of patient age, gender, steroid dose, and anthropometric data.
Conclusions In this pediatric population, cystatin C was not
superior to creatinine for the detection of acute allograft
dysfunction.
Keywords Allograftdysfunction.Kidneytransplantation.
Serumcreatinine.SerumcystatinC.Children.Acuterenal
failure.Pharmacokineticmodeling
Introduction
Allograft function following renal transplantation is com-
monly monitored using serum creatinine. Creatinine is not
an ideal marker of kidney function because its production is
dependent on age, gender, and muscle mass [1]. Due to
tubular secretion and extra-renal elimination via the gut,
serum creatinine concentrations may remain within the ref-
erence range until about 50% of kidney function has been
lost [2]. Because of lower muscle mass, creatinine produc-
tion in children is reduced compared to adults [3], which is
reflected in lower reference values. This may hamper the
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Cystatin C is an emerging endogenous marker of glomeru-
lar filtration rate (GFR; for review see [5, 6]), which has been
shown to be superior to serum creatinine for the detection of
mild to moderatechronic kidney dysfunction incross-sectional
studies both in adults with native kidney disease [7, 8]a n d
renal transplant recipients [9–11]. Recent data in adults admit-
ted to an intensive care unit indicate that cystatin C might also
be a more sensitive marker of acute renal dysfunction [12–14].
We therefore hypothesized that serum cystatin C might
be more sensitive than creatinine for the detection of acute
renal allograft dysfunction in children. As there are no data
on the performance of cystatin C in children with rapidly
changing GFR, we re-analyzed data from a previously
published cohort [15] using the recently developed pediatric
RIFLE criteria for acute renal injury [16, 17].
Methods
Patients
We performed a retrospective chart review of the post-
transplant period (from day 7 until hospital discharge) of
24 children (14 boys and 10 girls), who had received a
functioning graft at Hannover Medical School Children’s
Hospital between May 1996 and June 1997. Data on the first
7 days were not included to limit the effect of increased
cystatin C synthesis induced by high-dose corticosteroids
[18–20]. Patient age was 10.5 ± 5.1 years (mean ± standard
deviation), weight 34.2 ± 18.3 kg, height 134 ± 31.7 cm.
Half of the organs were from living related donors (four
from a father, eight from a mother). The immunosuppressive
regimen consisted of the microemulsion formulation of
cyclosporine A and prednisolone [15].
Assays
Cystatin C and creatinine were measured in parallel every
day. Creatinine was determined enzymatically using the
creatininase para-aminophenazone (PAP) assay (Boehringer
Mannheim, Mannheim, Germany). Cystatin C concentrations
were measured by particle-enhanced immunoturbidimetry
using the Cystatin PET-Kit (DAKO, Hamburg, Germany).
Both assays were performed on a Hitachi 717 autoanalyzer
(Boehringer Mannheim, Mannheim, Germany). Measure-
ments were performed in the same serum samples using
remnant material. Interassay precision was better for the
creatinine than for the cystatin C assay (coefficient of
variation 3.5% vs. 5.5% at concentrations of 13.7 µmol/l and
0.97 mg/l, and 1.6% vs. 4.7% at 79.1 µmol/l and 1.70 mg/l,
respectively [20].
Definition of allograft dysfunction
Episodesofallograftdysfunctionwereidentifiedinanalogyto
the approach used by Herget-Rosenthal [12] with several
modifications: From the daily measurements of cystatin
C and creatinine, we calculated the individual baseline con-
centration for each day as the mean of the three preceding
days. Acute allograft dysfunction was defined as a critical rise
in marker concentration above baseline on two consecutive
days. We used the pediatric RIFLE (risk of renal dysfunction,
injury to the kidney, failure or loss of kidney function, end
stage renal disease) criteria (pRIFLE) to define critical rises.
The pediatric RIFLE criteria are based on a decrease in
estimated glomerular filtration rate by 25% (pRIFLE 'R' indi-
cating risk of renal dysfunction), 50% (pRIFLE 'I', i.e., injury
to the kidney) and 75% (pRIFLE ‘F’, i.e., failure of kidney
function) [16]. Criteria ‘L’ and ‘E’, which are defined by need
for renal replacement therapy, were not applicable in our
study, as only patients with primary allograft function were
included and no patient required dialysis during our study.
Estimated glomerular filtration rate (eGFRcreat) was
calculatedfrombodyheightandserumcreatinineaccordingto
Schwartz [21]:
eGFRcreat mL=min=1:73 m2 
¼ Height cm ðÞ   36=serum creatinine μmol=L ðÞð 1Þ
As height was constant during the period of observation,
these criteria could be transformed into critical rises in
serum creatinine concentration:
eGFRcreatnew=eGFRcreatbaseline
¼ creatininebaseline=creatininenew ð2Þ
Using this transformation, stage 'Rcreat' corresponds to a
rise in serum creatinine by more than factor 1.33 above
baseline, stage 'Icreat' by more than factor 2 and stage 'Fcreat'
by more than factor 4.
For cystatin C, the Grubb equation [22]:
eGFRcys mL=min=1:73m2 ½  ¼ 84:69   cystatin C mg=L ðÞ
 1:680
 1:384 in children younger than 14 years ½ 
ð3Þ
was used to calculate the critical rise corresponding to a
decrease in GFR by 25, 50, and 75%. The Grubb equation
had been established in children with chronic kidney disease
(CKD) and after renal transplantation using the same DAKO
immunoturbidimetric assay as in our patients. Critical rises
in cystatin C concentration using this definition are 1.19
times baseline ('Rcys'), 1.51 ('Icys'), and 2.28 ('Fcys').
Day 0 of an episode of allograft dysfunction was defined
as the day directly preceding a rise in one or both marker
844 Pediatr Nephrol (2012) 27:843–849concentrations sufficient to meet the pRIFLE criterion ‘R’
(Fig. 1). We determined the time lag (in days) until the other
marker met the respective criterion.
Statistics
Statistical analysis was done using SPSS 16.0.1 (SPSS Inc.,
Chicago, IL, USA). Data are presented as median (inter-
quartile range IQR) unless otherwise indicated. Compari-
sons were performed using standard non-parametric tests. κ-
statistic was calculated for agreement between both markers
in the detection of allograft dysfunction. The maximum
relative rise in cystatin C concentration during each episode
of allograft dysfunction was studied by multiple linear re-
gression analysis including the parameters age, gender, ste-
roid dose, weight, height, and maximum rise in creatinine. p
values below 0.05 were considered statistically significant.
Due to the small sample size, statistical power is low.
Pharmacokinetic modeling
Kinetics of serum cystatin C and serum creatinine following
acute changes in glomerular filtration rate were simulated
using a one-compartment pharmacokinetic model with zero-
order input for a child with a body weight of 28 kg and a
body surface area of 1 m
2. For creatinine, we entered total
body water (i.e., 0.6 × body weight) as volume of distribu-
tion [23] and a production rate of 20 mg/kg/day [1]. For
cystatin C, volume of distribution is the extracellular fluid
compartment (i.e., 0.2 × body weight) [5] and production
rate 0.117 mg/min/1.73 m
2 [24]. Clearance was taken as
linear with glomerular filtration rate. Besides elimination by
glomerular filtration, we also entered extra-renal elimination
of cystatin C (i.e., 22.7 ml/min/1.73 m
2) into the model [24].
Thiswas not possiblefor creatinine, asextra-renal elimination
of creatinine increases with diminishing GFR and shows
large inter-individual variability [1].
Results
The median (IQR) of the mean cystatin C concentrations
found in the study subjects during the entire observation
period was 2.64 mg/l (1.83–3.65), for creatinine this was
97 µmol/l (56–173). Ondischarge, the median 24-h creatinine
clearance was 66 ml/min/1.73 m
2 (36–72), median cystatin C
concentration was 2.37 mg/l (1.83–3.29), median creatinine
91 µmol/l (56–135).
Fig. 1 Method for calculation of time-lag to fulfill RIFLE (risk of renal
dysfunction, injury to the kidney, failure or loss of kidney function, end
stage renal disease) criteria. The grey marker reaches "RIFLE R" on
day + 1 (arrow), which defines the start of the episode. The mean
concentration of day –2 to day 0 is used as baseline for calculation of
the time-lag. In the example, "RIFLE F" is reached on day +3 by the
marker presented in grey and on day +4 by the black marker
Table 1 Factors influencing the maximum rise in serum cystatin C.
Presentation of the slopes (B) representing the correlation with the
maximal relative rise of cystatin C, with 95% confidence intervals
(95% CI) calculated using multiple linear regression analysis
B 95% CI p value
Max relative rise Crea 0.491 0.365 to 0.617 < 0.001
Gender (m 0 1) –0.019 –0.383 to 0.345 0.914
Age (years) –0.03 –0.176 to 0.116 0.67
Weight (kg) +0.002 –0.018 to 0.022 0.806
Height (cm) +0.001 –0.030 to 0.032 0.922
Steroid dose (mg/m
2/day) –0.005 –0.029 to 0.019 0.666
Fig. 2 a, b Pharmacokinetic models illustrating the relative rise of
creatinine above baseline at different levels of glomerular filtration rate
(GFR) in time. Course of calculated creatinine concentrations follow-
ing an acute decrease in GFR at time 24 h at two different levels of
GFR. Presentation of the relative rise compared to baseline corre-
sponds to a GFR of 100 ml/min/1.73 m
2 (Fig. 2a) and a GFR of
50 ml/min/1.73 m
2 (Fig. 2b)
Pediatr Nephrol (2012) 27:843–849 845In total, there were 13 episodes of kidney dysfunction:
nine rejections (six proven by biopsy), one pyelonephritis,
and one case of cyclosporine toxicity. In two episodes, no
etiology was found. Maximum RIFLE stages were 'Rcreat'i n
seven, 'Icreat'i nf o u r ,a n d' F creat' in two episodes using
creatinine compared to ‘R cys', in six, 'Icys' in four, and 'Fcys'
in three episodes with cystatin C. Both markers rose simul-
taneously innineepisodes.Inthreecases,theriseincreatinine
Table 2 Presentation of the time
in hours needed by cystatin C
and creatinine concentrations
to reach a new steady state fol-
lowing acute changes in glo-
merular filtration rate (GFR) at
different levels of baseline GFR:
chronic kidney disease (CKD) 1,
100 ml/min/1.73 m
2; CKD 2,
75 ml/min/1.73 m
2; CKD 3,
50 ml/min/1.73 m
2;
and CKD 4, 25 ml/min/1.73 m
2.
For cystatin C, two calculations
were done: first, only renal
elimination was considered,
and second, extra-renal
elimination (ERE) was also
entered into the model
Time to new steady state [h]
Creatinine Cystatin C Cystatin C + ERE
CKD 1 R (–25%) 22 7 6
I( –50%) 34 11 8
F( –75%) 71 24 12
CKD 2 R (–25%) 30 10 7
I( –50%) 45 15 10
F( –75%) 89 30 14
CKD 3 R (–25%) 45 15 9
I( –50%) 67 22 12
F( –75%) 134 45 16
CKD 4 R (–25%) 90 30 14
I( –50%) 134 45 16
F( –75%) 268 89 19
Fig. 3 a, b, c, and d Pharmacokinetic models illustrating the relative
rise of cystatin C above baseline at different levels of glomerular
filtration rate (GFR) in time. Course of calculated cystatin C concen-
trations following an acute decrease in GFR at time 24 h at two
different levels of GFR. Presentation of the relative rise compared to
baseline corresponds to a GFR of 100 ml/min/1.73 m
2 (Fig. 3a and c)
and a GFR of 50 ml/min/1.73 m
2 (Fig. 3b and d). In Fig. 3c and d, the
extrarenal elimination (ERE) of cystatin C (i.e., 22 ml/min/1.73 m
2)i s
taken into account. For comparison, the relative rise of cystatin C calcu-
lated according to the Grubb equation is indicated in Fig. 3c and d
846 Pediatr Nephrol (2012) 27:843–849preceded cystatin C by 1 to 5 days (median 4 days). In
only one case the rise in cystatin C preceded creatinine
by 1 day. The time lag was not statistically different
(z 0 –1.289, p 0 0.197; Wilcoxon test).
The median (IQR) of the maximum concentration of
cystatin C during the individual episodes of allograft dys-
function was 4.15 mg/l (2.68–4.92). For creatinine, this was
160 µmol/l (98–268). In terms of relative rise above base-
line,thiswasbyafactorof1.59(1.35–2.28)forcystatinCand
1.9 (1.56–2.95) for creatinine (p 0 0.002, Wilcoxon test).
The maximum relative rise of cystatin C above base-
line was related to the maximum relative rise of creatinine
(Table 1) but independent of patient age, gender, steroid dose,
and anthropometric data. The slope of 0.491 reflects the
stronger relative rise in creatinine than cystatin C.
Analysis of the agreement between cystatin C and creat-
inine in the detection of RIFLE stage yielded a κ-value of
0.683.
The kinetics of creatinine following an acute decrease in
GFR is modeled in Fig. 2a and b. As predicted from Eq. (2),
the relative rise in serum creatinine is times 1.33, 2, and 4,
and independent of baseline GFR. The time to reach a new
steady state is longer with low baseline GFR (Table 2). The
pharmacokinetics of cystatin C are shown in Fig. 3a–d.
When considering only renal elimination of cystatin C
(Fig. 3a and b), the relative rise is identical to creatinine,
yet the time to reach a new steady state is considerably
shorter due to the smaller volume of distribution (Table 2).
When extra-renal elimination of cystatin C is also entered
into the model, the relative rise decreases, which is more
pronounced at lower baseline GFR (Fig. 3c and d). The
model including extra-renal elimination shows better agree-
ment with the steady-state concentrations calculated from
the Grubb equation.
In Fig. 4, the effect of corticosteroids on the relative
rise of cystatin C above baseline is illustrated at differ-
ent levels of GFR. It shows that corticosteroids increase
the relative rise in cystatin C, namely in patients with low
GFR.
Discussion
Although there is an abundance of cross-sectional studies
comparing the diagnostic performance of cystatin C and
creatinine, very few have addressed serial changes of these
markers in acute renal failure. This can be done using
exposure to an acute nephrotoxin such as intravenous radio-
contrast fluid or cisplatin [13, 25, 26] or a well-defined
insult holding a high risk of acute renal failure, such as
major cardiovascular surgery [14]. Using a gold standard
GFR measurement, Benöhr et al. found a significant decrease
in GFR by 22%, 5 days following cisplatin administration,
which was reflected by a significant rise in serum cystatin C
by 14% while serum creatinine concentrations remained
unchanged. However, following intravenous radiocontrast
administration, both Rickli et al. [25] and Poletti et al. [26]
found no difference between cystatin C and creatinine during
a follow-up of 2 to 4 days.
The present study analyzed serial changes in kidney
function during the first weeks after renal transplantation,
a period in which allograft function is monitored on a daily
basis and where there is a high risk of renal dysfunction.
During 13 episodes of acute allograft dysfunction, we ob-
served no difference in sensitivity between both markers,
while the relative rise in creatinine concentration was stron-
ger than in cystatin C. Using a similar approach in adults,
Herget-Rosenthal [12] found a significantly earlier rise in
cystatin C than creatinine allowing prediction of acute renal
injury 1 to 2 days before creatinine.
When comparing both studies, several differences have
to be considered. (i) The pediatric definition of acute renal
injury [16] is based on a decrease in estimated GFR from
baseline by 25, 50, and 75%. This corresponds to an in-
crease in serum creatinine by factor 1.33, 2.0, and 4.0 and
by factor 1.19, 1.51, and 2.28 for cystatin C, respectively.
This should have favored cystatin C in our study, however,
as Herget-Rosenthal used the adult RIFLE staging [27] for
both creatinine and cystatin C with ‘R’ corresponding to 1.5,
‘I’ to 2.0 and ‘F’ to 3.0 times baseline concentration. (ii)
Herget-Rosenthal excluded patients with glucocorticoid
Fig. 4 Model illustrating the effect of corticosteroids on the relative rise
ofcystatinCabovebaselineatdifferentlevelsofglomerularfiltrationrate
(GFR). Calculation of cystatin C concentrations correspond to three
different baseline GFR levels and a decrease by 25% (RIFLE ‘R’)u s i n g
the Grubb equation. Correction for the dose-dependent increase in serum
cystatin C caused by glucocorticoids using the equation 1/cys 0 0.0096
*G F R– 0.0023 * prednisone dose (mg/m
2/day) [33]
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interfere with cystatin C metabolism [28, 29]. Thyroid func-
tion was not measured in our patients, but it appears very
unlikely that the attenuated rise in cystatin C can be attrib-
uted to untreated hypothyroidism in these asymptomatic
renal transplant recipients. Being part of the standard immu-
nosuppressive regimen, all of our patients received large
doses of glucocorticosteroids known to cause a dose-
dependent induction of cystatin C synthesis [30] and higher
baseline cystatin C concentrations [15]. Therefore, we ex-
cluded the first 7 days post-transplant. From day 8 onwards,
mean serum creatinine and cystatin concentrations were
constant in relation to each other indicating that a new
equilibrium had been reached [15]. Also, corticosteroid dose
was not related to the maximum rise in cystatin C during
acute allograft dysfunction by multivariate analysis. In fact,
corticosteroids increase the relative rise in cystatin C, name-
ly in patients with low GFR, as illustrated in Fig. 4. (iii) The
most likely explanation is the difference in kidney function
of the patient populations. As shown by our pharmacoki-
netic model, the effect of the extrarenal elimination of
cystatin C increases at lower baseline GFR, leading to an
attenuated rise in serum cystatin C. All patients in the cohort
of Herget-Rosenthal had normal kidney function at baseline,
whereas GFR in our transplant recipients was around 60 to
70 ml/min/1.73 m
2. Also, looking at their data, the
stronger increase in cystatin C compared to creatinine
was most marked at low normal GFR (RIFLE ‘R’)a n d
vanished when kidney failure had progressed to RIFLE
‘F’.
Our study has several limitations. The statistical power is
low, calling for larger prospective studies in the critical
cohort of patients with pre-existing renal disease and renal
transplant recipients. Also, we did not measure GFR by a
gold standard technique, as this is not feasible on a daily
basis. The diagnosis of acute renal injury was based on the
course of kidney function parameters without having a
definitive diagnosis of the underlying problem in each case.
Still, our definition requiring a sustained increase lasting at
least 2 days and the overall good agreement between creat-
inine and cystatin C indicate that the diagnosis of acute
kidney injury was correct. Our strict definition excluded
short-term fluctuations of GFR, a potential stronghold of
cystatin C [31].
In conclusion, cystatin C was not superior to creatinine
for the detection of acute allograft dysfunction in this pedi-
atric series of limited sample size. The potential of cystatin
C as a marker of acute renal dysfunction needs further
evaluation in adequately powered studies and should be
compared with novel markers of renal injury like N-GAL
(neutrophil gelatinase-associated lipocalin), which originate
from damaged kidney tissue rather than reflecting a decrease
in GFR [32].
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